Biotech Fundraising: What is Different?

Biotech fundraising operates by different rules than software startups. Longer timelines, higher capital requirements, and regulatory complexity create a unique investor landscape. Understanding these differences is critical for life sciences founders.

How Biotech Differs from Software

| Factor | Software Startups | Biotech Startups |

|--------|------------------|------------------|

| Time to Revenue | 6-18 months | 5-15 years |

| Capital Required | $1-20M to profitability | $100M-$1B+ to approval |

| Failure Rate | 70-80% | 90%+ (drug development) |

| Exit Timeline | 5-10 years | 10-20 years |

| Revenue Model | Recurring/transactional | Binary (approval or not) |

| Key Milestones | Users, revenue, growth | Clinical data, FDA approval |

The Biotech Funding Stages

Stage 1: Discovery/Platform ($1M-$10M)

Focus: Validating the science

• Proof of concept data
• Target validation
• Platform development
• Early IP filing

Typical investors: Grants, angels, small biotech VCs, academic funds

Stage 2: Preclinical ($10M-$50M)

Focus: Preparing for human trials

• Lead compound optimization
• IND-enabling studies
• Manufacturing process development
• Toxicology studies

Typical investors: Series A biotech VCs

Stage 3: Phase 1/2 ($30M-$100M)

Focus: Early human trials

• Safety and dosing studies
• Early efficacy signals
• Patient enrollment
• Biomarker development

Typical investors: Series B investors, crossover funds

Stage 4: Phase 3 ($100M-$500M+)

Focus: Pivotal trials for approval

• Large-scale efficacy trials
• Regulatory submissions
• Commercial preparation
• Manufacturing scale-up

Typical investors: Crossover funds, public markets, pharma partnerships

What Biotech Investors Evaluate

1. Scientific Foundation

| Element | What Investors Want |

|---------|--------------------|

| Mechanism of Action | Novel, validated biology |

| Data Quality | Reproducible, peer-reviewed |

| IP Position | Broad, defensible patents |

| Platform Potential | Multiple programs possible |

2. Clinical Strategy

• Regulatory pathway - Clear FDA strategy
• Indication selection - Appropriate patient population
• Trial design - Endpoints that will support approval
• Competitive landscape - Differentiation from alternatives

3. Team Composition

Essential roles:

• Scientific founder - Deep domain expertise
• Drug development experience - Someone who has done it before
• Clinical leadership - Trial design and execution
• Regulatory expertise - FDA navigation

4. Capital Efficiency

• Milestone-based funding - Clear use of capital
• Risk mitigation - Derisking strategy
• Partnership potential - Pharma interest
• Alternative paths - Options if trials fail

Types of Biotech Investors

Dedicated Life Sciences VCs

| Firm | Stage Focus | Notable |

|------|-------------|--------|

| Third Rock Ventures | Company creation | Built Moderna |

| Flagship Pioneering | Platform creation | Created Moderna |

| Atlas Venture | Seed/Series A | Long track record |

| ARCH Venture Partners | Early stage | Deep science focus |

| Versant Ventures | Early to growth | Company building |

What they bring:

• Scientific expertise for diligence
• Drug development experience
• Pharma relationships
• Patient capital

Crossover Investors

Funds that invest in both private and public biotech:

• RA Capital
• OrbiMed
• Baker Brothers
• Perceptive Advisors

When they invest: Late-stage privates, IPO participation, post-IPO

Strategic Investors (Pharma)

Corporate venture arms of pharmaceutical companies:

• Advantages: Validation, partnership potential, expertise
• Disadvantages: Potential conflicts, slower decisions, strategic strings

Government and Foundation Funding

• NIH grants - SBIR/STTR programs
• BARDA - Biodefense and pandemic preparedness
• Disease foundations - Patient advocacy organizations
• State programs - Life sciences incentives

Biotech-Specific Deal Structures

Common Instruments

| Structure | When Used | Key Terms |

|-----------|-----------|----------|

| Preferred equity | Most rounds | Liquidation preference, anti-dilution |

| Milestone-based tranches | High-risk stages | Capital released on data |

| Synthetic biology royalties | Platform plays | Revenue share on programs |

| Warrants | Bridge financing | Upside participation |

Milestone-Based Funding

Common in biotech to reduce risk:

• Tranche 1: Initial capital for key experiment
• Tranche 2: Released upon positive data
• Tranche 3: Released upon IND filing

Founder consideration: Understand dilution implications if milestones are missed.

Biotech Valuation Drivers

Key Factors

• Clinical data - Positive results dramatically increase value

• Stage advancement - Each stage cleared adds value

• Market size - Indication potential

• Competitive position - First-in-class vs. best-in-class

• IP strength - Patent protection duration

• Team quality - Execution credibility

Valuation Benchmarks (2025)

| Stage | Typical Valuation Range |

|-------|------------------------|

| Seed/Platform | $5M-$30M |

| Series A (preclinical) | $30M-$100M |

| Series B (Phase 1/2) | $100M-$400M |

| Series C/Pre-IPO | $400M-$1B+ |

Common Biotech Fundraising Mistakes

1. Underestimating Capital Needs

Biotech always takes more money and time than planned. Build buffer into projections.

2. Wrong Investor Type

Generalist tech VCs often do not understand biotech timelines and risk profiles.

3. Ignoring Regulatory Strategy

FDA pathway should be clear from the start, not an afterthought.

4. Weak IP Position

Patent strategy is critical. Engage patent counsel early.

5. Team Gaps

Investors want to see drug development experience, not just scientific founders.

Preparing for Biotech Fundraising

Materials Needed

• Scientific presentation - Mechanism, data, competitive landscape

• Development plan - Timeline, milestones, capital needs

• Regulatory strategy - FDA pathway, trial design

• IP summary - Patent portfolio, freedom to operate

• Team bios - Relevant drug development experience

• Financial projections - Capital needs by stage

Building Investor Relationships

• Start early - 12-18 months before you need capital
• Scientific conferences - JPM Healthcare, BIO, ASCO
• Publish data - Peer-reviewed credibility
• Advisory relationships - Strategic advisors open doors

Alternative Funding Sources

Non-Dilutive Capital

| Source | Typical Amount | Best For |

|--------|---------------|----------|

| NIH SBIR/STTR | $250K-$2M | Early research |

| BARDA | $10M-$500M | Infectious disease, biodefense |

| Disease foundations | $100K-$5M | Specific indications |

| State grants | $100K-$1M | Local job creation |

Pharma Partnerships

Structures include:

• Research collaborations - Funded research programs
• Option deals - Right to acquire/license
• Co-development - Shared costs and economics
• Licensing - Upfront + milestones + royalties

Key Takeaways

• Biotech is a different game - Longer timelines, higher capital, different metrics

• Target specialized investors - Generalist VCs often do not fit

• Scientific credibility matters - Data and publications build trust

• Team experience is critical - Drug development expertise required

• Milestone-based thinking - Value created at clinical inflection points

• Capital efficiency - Do more with less before each raise

Resources

• NIH SBIR/STTR: sbir.nih.gov
• BIO Convention: bio.org
• JP Morgan Healthcare Conference: Annual industry gathering
• Endpoints News: Industry publication